Lonza to double production of Covid-19 vaccine at Swiss plant
Lonza has struggled to recruit enough workers to join its Visp plant, which now has three production lines set up and plans three more by early 2022.
Keystone / Olivier Maire
Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort to boost the global supply of doses.
This content was published on
2 minutes
swissinfo.ch/SRF/gw
Español
es
Lonza duplicará la producción de la vacuna COVID-19 en su planta suiza
The new production lines will be added gradually to three existing lines and be fully operational by early 2022, Lonza said on Thursday. The two companies signed a ten-year contract in 2020 that enables Lonza to make a drug substance for the mRNA vaccine at its plant for the global market outside the United States.
In a separate press release, Moderna said it planned to increase the overall supply to up to three billion doses by 2022. The firm calculates there will be greater demand for its vaccine as the need for booster shots is likely to grow starting next year.
The announcement comes as Lonza struggles to recruit enough workers to join its Visp plant. Biotech specialists are currently in high demand worldwide as a result of the pandemic, Swiss public television, SRF, reported, adding that the interior ministry is now actively helping Lonza to find specialists from inside the federal administration and universities, including the federal technology institutes ETH Zurich and the EPFL in Lausanne.
Lonza has reportedly recruited temporary staff from food giant Nestlé with help from the Swiss government. Moderna has blamed projected delays in shipments of the vaccine to markets such as the UK and Canada on production bottlenecks, according to Reuters.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Free trade remains ‘core’ Swiss value despite Trump tariffs
This content was published on
Swiss President Karin Keller-Sutter says Switzerland remains committed to free trade despite a new 31% tariff on Swiss exports to the United States.
This content was published on
The new regulation targets plants developed through new breeding technologies that don’t include transgenic genetic material.
WHO faces $1.8 billion budget shortfall amid US withdrawal
This content was published on
The 2026-2027 budget for the Geneva-based organisation has been reduced to $4.2 billion, on top of this year’s $600 million shortfall.
Swiss government proposes lifting nuclear power ban
This content was published on
While the centre-right and the energy sector are welcoming the Swiss government’s counter-proposal, the Greens are threatening to call a referendum.
Switzerland provisionally signs agreement on EU programmes
This content was published on
The agreement on EU programmes covers Switzerland’s involvement in initiatives like Horizon Europe, Euratom, ITER, Digital Europe, Erasmus+, and EU4Health.
Record-breaking winter for Swiss tourism driven by foreign visitors
This content was published on
A survey by Switzerland Tourism suggests this winter has outdone last season's record, largely thanks to foreign visitors and favourable weather conditions.
Swiss study predicts rise in global antibiotic use in farming
This content was published on
Global antibiotic use in livestock farming could rise by 2040, says a study by FAO and the University of Zurich. Switzerland expects minimal change.
Swiss firm Lonza to help produce anti-Covid nasal spray in the US
This content was published on
As part of its agreement with American company Altimmune, Lonza will allocate a dedicated manufacturing facility for AdCOVID nasal spray vaccine.
Switzerland mulls future European coordination on medical supplies
This content was published on
“The pandemic has shown us that we are very dependent, maybe too much so, on other markets,” Swiss President Guy Parmelin has said.
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.